Small-Cap Maravai LifeSciences’ Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 Guidance

Thursday, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) reported fourth-quarter 2023 revenue of $74.1 million, beating the consensus of $64.38 million.

The company reported a net loss of $(110.0) million following a valuation adjustment to certain deferred tax assets and an adjusted EBITDA margin of 28%.

Adjusted EPS of $0.01 came below $0.35 a year ago but surpassed the estimated $(0.01) loss.

“We closed out a challenging 2023 with better than forecasted demand for our Nucleic Acid Production products, including for CleanCap and custom chemistry,” said Trey Martin, Chief Executive Officer of Maravai.

“Thanks to our team’s strong execution, the cost reductions …

Full story available on Benzinga.com